| Date | Title | Description |
| 30.07.2026 | Verdiva Bio Initiates Phase 1 Study of VRB-103, a Selective Oral Amylin Peptide Analog With Weekly Dosing Potential | Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral candidates for obesity and obesity-related disorders, today announces that the first p... |
| 23.07.2026 | Verdiva Bio Appoints Cardiometabolic Leader Steve Marso as Chief Medical Officer | Verdiva Bio Limited (“Verdiva Bio” or the “Company”), a clinical-stage biotechnology company advancing the development of a portfolio of once-weekly oral therapies for obesity and obesity-related disorders, today announced that it has stren... |
| 07.05.2026 | Healthtech: 10 companies that raised the most in 2025 | In 2025, Europe’s healthtech ecosystem showed strong funding momentum, with capital concentrated in large rounds across biotech, medtech, digital health, and AI-enabled healthcare. The biggest deals came from companies such as Oura Health, ... |
| 26.02.2026 | Revolut: Digital Powerhouse Redefines Global Finance Amidst Regulatory Scrutiny | Revolut, the UK fintech titan, achieved a $75 billion valuation in 2025, disrupting traditional banking. Global expansion remains a priority, marked by a Mexico banking launch. However, a full UK banking license still eludes the firm, amids... |
| 06.02.2026 | From big rounds to broad momentum: the UK tech ecosystem | In 2025, the UK led European tech investment by a wide margin, raising €21.5 billion across 830 deals and topping investment volumes in every quarter of the year.
Funding was driven by a small number of very large transactions alongside a b... |
| 15.01.2026 | UK VC Investment Rebounds in 2025 | UK startups and scaleups raised $23.6 billion in venture capital funding in 2025, a 35% increase on 2024 and the first annual growth in UK VC investment in four years, according to new analysis from HSBC Innovation Banking UK and Dealroom.
... |
| 10.01.2026 | 2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market | In 2026, new obesity pills will push the booming GLP-1 market into its next chapter.
Pills may serve as a more convenient — and in certain cases cheaper — alternative to today’s blockbuster injections that could attract entirely new patient... |
| 15.09.2025 | Europe's VC Shift: UK Fights for Lead as Healthtech Soars in 2025 | European venture capital is undergoing significant shifts in 2025. The UK remains a leader, but emerging competition from Germany and France is notable. Healthtech and AI innovation are major investment drivers, securing billions across the... |
| 11.09.2025 | Europe's 10 biggest healthtech deals in H1 2025 | Healthtech continued to demonstrate its strength in Europe in the first half of 2025, attracting €4 billion in funding, around 12 per cent of the €33.7 billion raised across all European tech sectors. Although healthtech accounted for just ... |
| 23.04.2025 | The Surge of Innovation: Healthtech and Energy Solutions in Europe | In the heart of Europe, a financial storm is brewing. The healthtech and AI sectors are not just weathering the global economic climate; they are thriving. In the first quarter of 2025, European healthtech and AI startups raised a staggerin... |
| 22.04.2025 | Europe’s healthtech and AI startups raise $13.9B in Q1 as global investors return | Q1 data from Dealroom reveals that European health tech and AI companies continue to attract significant interest from global venture capital investors, with $13.9 billion raised in the first quarter of 2025.
This represents a 2 per cent ye... |
| 17.04.2025 | London startups bag £2.69bn in VC funding in 2025 so far | London-based startups attracted £2.69bn in venture capital (VC) in the first three months of the year, marking a robust start of the year despite a fall in deal volumes.
According to KPMG’s latest venture pulse report, while deal count drop... |
| 14.04.2025 | Health Tech Leads UK VC Investment in 2025 Q1 | UK health tech and life sciences startups raised $1.8 billion in venture capital investment in Q1 2025, the sector’s second strongest quarter on record, according to new analysis from HSBC Innovation Banking UK and Dealroom.
Health was the ... |
| 14.04.2025 | UK surges ahead of France and Germany as Europe’s ‘innovation powerhouse’ | HSBC Innovation Banking, a subsidiary of Europe’s biggest lender, hailed the UK’s enterprise value in its latest innovation report.
UK innovation firms raised £3.2bn of venture capital in the first three months of the year – an eight per ce... |
| 27.02.2025 | Biotech Startup Eikon Therapeutics Locks Up Massive $351M Series D | 3 Shares Email Facebook Twitter LinkedIn
Startup Eikon Therapeutics raised one of the biggest biotech rounds thus far in this young year.
The Hayward, California-based drug startup closed on nearly $351 million in a Series D from the likes ... |
| 10.02.2025 | January 2025's top 10 European tech deals you need to know about | According to the Tech.eu database, European tech companies raised €6.6 billion throughout January 2025. In comparison to the same period in previous years, January 2025 experienced a notable decline of about 60 per cent compared to 2024, bu... |
| 13.01.2025 | Verdiva Bio Raises Over $410M in Series A Financing | Verdiva Bio, a London, UK-based clinical-stage biopharmaceutical company, raised over $410M in Series A Funding.
The round was led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly... |
| 12.01.2025 | European Tech Landscape: A Surge of Innovation and Investment | The European tech scene is buzzing. A recent wave of funding, acquisitions, and innovative breakthroughs paints a vibrant picture of the continent's entrepreneurial spirit. This week alone, over 40 tech funding deals topped €1.3 billion. Th... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A raise for next-gen oral and injectable treatments for obesity | Pharmatech company Verdiva Bio launched this week with an eye-watering $411 million Series A.
Focused on developing innovative therapies for obesity and other cardiometabolic disorders, Verdiva Bio is creating next-generation oral and injec... |
| 10.01.2025 | Verdiva Bio launches with $411M Series A, European startups triumph at CES, and European highest fundraisers in 2024 | This week we tracked more than 40 tech funding deals worth over €1.3 billion, and over 20 exits, M&A transactions, rumours, and related news stories across Europe. In addition to this week's top financials, we've also indexed the most i... |
| 10.01.2025 | Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio | HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaborati... |
| 09.01.2025 | Forbion Co-Leads over $410M Series A Financing to Launch Verdiva Bio, a Clinical-Stage Cardiometabolic Company Advancing Next-Generation Therapies | - Co-founded by Khurem Farooq and former members of Aiolos Bio team to develop broad portfolio of oral and injectable treatments for obesity, cardiometabolic disorders, and related complications
- Forbion played an instrumental role in the ... |
| 09.01.2025 | Verdiva launches with $410M series A to fund weekly-dosed weight loss drug trials, pipeline growth | Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has arrived on the scene with an eye-popping series A.
The London-headquartered company has persuaded backers to put down $... |
| - | Verdiva Bio | “Verdiva Bio is committed to developing next-generation therapies to help people living with obesity, cardiometabolic disorders, and related complications achieve better outcomes via more patient-friendly therapeutic options.” |
